{"entity":{"id":"patil-vijay","kind":"person","name":"Vijay Patil","aka":[],"tldr":"Showed that very low-dose nivolumab added to cheap chemotherapy improves survival in head and neck cancer, a landmark for affordable immunotherapy.","summary":"Vijay Patil is Professor of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai, specialising in head and neck oncology. He led the randomised trial of low-dose nivolumab added to triple metronomic chemotherapy in advanced head and neck cancer, which showed that very low-dose immunotherapy combined with cheap chemotherapy improves outcomes at a fraction of the cost of standard dosing, a landmark for affordable immunotherapy. His publications include the randomised study of low-dose immunotherapy in head and neck cancer. His interests are low-dose immunotherapy, metronomic chemotherapy and pragmatic trials.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patil%20VM%5BAuthor%5D%20low-dose%20nivolumab%20head%20and%20neck"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Tata Memorial Hospital; head and neck oncology","institutionId":"tata-memorial","specialisms":["Head and neck cancer","Low-dose immunotherapy","Metronomic chemotherapy","Pragmatic trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patil%20VM%5BAuthor%5D%20low-dose%20nivolumab%20head%20and%20neck"}],"papers":[{"title":"Low-dose immunotherapy in head and neck cancer: a randomized study","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.01015"}]},"route":"/people/patil-vijay/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"idea":[{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/"}],"trial":[{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/"},{"id":"metronomic-vs-cisplatin-tmh","kind":"trial","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","route":"/trials/metronomic-vs-cisplatin-tmh/"}],"paper":[{"id":"paper-patil-low-dose-nivolumab-jco-2023","kind":"paper","name":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","route":"/key-papers/paper-patil-low-dose-nivolumab-jco-2023/"}]}}